PT2421534E - Formulações líquidas de sais de 1-[2-(2,4-dimetilfenilsulfanil)fenil]-piperazina - Google Patents
Formulações líquidas de sais de 1-[2-(2,4-dimetilfenilsulfanil)fenil]-piperazina Download PDFInfo
- Publication number
- PT2421534E PT2421534E PT107141640T PT10714164T PT2421534E PT 2421534 E PT2421534 E PT 2421534E PT 107141640 T PT107141640 T PT 107141640T PT 10714164 T PT10714164 T PT 10714164T PT 2421534 E PT2421534 E PT 2421534E
- Authority
- PT
- Portugal
- Prior art keywords
- dimethylphenylsulfanyl
- piperazine
- phenyl
- salts
- liquid formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
- Lubricants (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21454009P | 2009-04-24 | 2009-04-24 | |
| DKPA200900531 | 2009-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2421534E true PT2421534E (pt) | 2014-10-29 |
Family
ID=42669509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT107141640T PT2421534E (pt) | 2009-04-24 | 2010-04-16 | Formulações líquidas de sais de 1-[2-(2,4-dimetilfenilsulfanil)fenil]-piperazina |
Country Status (35)
| Country | Link |
|---|---|
| US (4) | US8940746B2 (pt) |
| EP (1) | EP2421534B1 (pt) |
| JP (1) | JP5722879B2 (pt) |
| KR (1) | KR101779214B1 (pt) |
| CN (2) | CN102405048A (pt) |
| AR (2) | AR076400A1 (pt) |
| AU (1) | AU2010238946B2 (pt) |
| BR (1) | BRPI1015338C1 (pt) |
| CA (1) | CA2759456C (pt) |
| CL (1) | CL2011002631A1 (pt) |
| CO (1) | CO6450649A2 (pt) |
| CR (1) | CR20110554A (pt) |
| DK (1) | DK2421534T3 (pt) |
| DO (2) | DOP2011000319A (pt) |
| EA (1) | EA021122B1 (pt) |
| ES (1) | ES2512719T3 (pt) |
| GE (1) | GEP20135938B (pt) |
| HK (1) | HK1206732A1 (pt) |
| HR (1) | HRP20140880T1 (pt) |
| IL (1) | IL215362A0 (pt) |
| MA (1) | MA33298B1 (pt) |
| MX (1) | MX2011011119A (pt) |
| MY (1) | MY155288A (pt) |
| NZ (1) | NZ596431A (pt) |
| PL (1) | PL2421534T3 (pt) |
| PT (1) | PT2421534E (pt) |
| RS (1) | RS53539B1 (pt) |
| SG (1) | SG175124A1 (pt) |
| SI (1) | SI2421534T1 (pt) |
| SM (1) | SMT201400159B (pt) |
| TN (1) | TN2011000504A1 (pt) |
| TW (1) | TWI461224B (pt) |
| UA (1) | UA106985C2 (pt) |
| WO (1) | WO2010121621A1 (pt) |
| ZA (1) | ZA201107731B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ596431A (en) | 2009-04-24 | 2012-12-21 | Lundbeck & Co As H | Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
| US9499504B2 (en) | 2012-09-19 | 2016-11-22 | Sandoz Ag | Crystalline form of vortioxetine hydrobromide |
| AU2014286308B2 (en) | 2013-07-01 | 2018-05-10 | Lek Pharmaceuticals D.D. | 1-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline form |
| US9822086B2 (en) | 2014-01-31 | 2017-11-21 | Egis Gyogyszergyar Zrt. | Process for the preparation of vortioxetine salts |
| CN104146953A (zh) * | 2014-07-24 | 2014-11-19 | 李雪梅 | 一种氢溴酸沃替西汀注射液 |
| CN104119298B (zh) * | 2014-08-13 | 2016-08-24 | 北京蓝贝望生物医药科技股份有限公司 | 氢溴酸沃赛汀或氢溴酸沃替西汀 |
| CN104119299B (zh) * | 2014-08-13 | 2016-08-17 | 北京蓝贝望生物医药科技股份有限公司 | 沃赛汀或沃替西汀的氢溴酸盐 |
| GB201419261D0 (en) * | 2014-10-29 | 2014-12-10 | Therakind Ltd | Formulations |
| WO2016125190A2 (en) | 2015-02-04 | 2016-08-11 | Mylan Laboratories Limited | Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof |
| JO3456B1 (ar) * | 2015-05-13 | 2020-07-05 | H Lundbeck As | فيروتيوكسيتين بيروجلوتامات |
| CN108473451B (zh) | 2016-02-08 | 2022-07-15 | H.隆德贝克有限公司 | 1-[2-(2,4-二甲基-苯基硫烷基)-苯基]哌嗪的合成 |
| US9820984B1 (en) | 2016-07-01 | 2017-11-21 | H. Lundbeck A/S | Dosing regimens for fast onset of antidepressant effect |
| CN106518807A (zh) * | 2016-09-17 | 2017-03-22 | 北京万全德众医药生物技术有限公司 | 乳酸沃替西汀晶型的制备方法 |
| US10519121B2 (en) | 2016-12-30 | 2019-12-31 | Apicore Us Llc | Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts |
| CN107011289A (zh) * | 2017-03-10 | 2017-08-04 | 万全万特制药（厦门）有限公司 | 沃替西汀β晶型的制备方法 |
| GB2564887A (en) * | 2017-07-26 | 2019-01-30 | Azad Pharmaceutical Ingredients Ag | New route of synthesis to vortioxetine salts |
| WO2021198778A1 (en) | 2020-04-03 | 2021-10-07 | H. Lundbeck A/S | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA81749C2 (uk) * | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
| US7732463B2 (en) | 2003-04-04 | 2010-06-08 | H. Lundbeck A/S | 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors |
| SI2044043T2 (sl) * | 2006-06-16 | 2021-04-30 | H. Lundbeck A/S | 1-2(-2,4-dimetilfenilsulfanil)-fenil)piperazin hidrobromid kot spojina s kombinirano aktivnostjo ponovnega privzema serotonina, 5-ht3 in 5-ht1a za zdravljenje kognitivne motnje |
| CA2656057C (en) * | 2006-06-16 | 2012-10-02 | H. Lundbeck A/S | Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain |
| TWI405588B (zh) * | 2007-03-20 | 2013-08-21 | Lundbeck & Co As H | ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物 |
| TW200848411A (en) * | 2007-03-20 | 2008-12-16 | Lundbeck & Co As H | Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine |
| NZ596431A (en) | 2009-04-24 | 2012-12-21 | Lundbeck & Co As H | Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine |
-
2010
- 2010-04-16 NZ NZ596431A patent/NZ596431A/xx unknown
- 2010-04-16 ES ES10714164.0T patent/ES2512719T3/es active Active
- 2010-04-16 GE GEAP201012423A patent/GEP20135938B/en unknown
- 2010-04-16 BR BRPI1015338A patent/BRPI1015338C1/pt active IP Right Grant
- 2010-04-16 KR KR1020117025009A patent/KR101779214B1/ko active IP Right Grant
- 2010-04-16 EA EA201171287A patent/EA021122B1/ru not_active IP Right Cessation
- 2010-04-16 PT PT107141640T patent/PT2421534E/pt unknown
- 2010-04-16 EP EP10714164.0A patent/EP2421534B1/en active Active
- 2010-04-16 TW TW099111946A patent/TWI461224B/zh active
- 2010-04-16 US US13/265,564 patent/US8940746B2/en active Active
- 2010-04-16 AU AU2010238946A patent/AU2010238946B2/en active Active
- 2010-04-16 DK DK10714164.0T patent/DK2421534T3/da active
- 2010-04-16 SG SG2011073384A patent/SG175124A1/en unknown
- 2010-04-16 WO PCT/DK2010/050084 patent/WO2010121621A1/en active Application Filing
- 2010-04-16 CN CN2010800171058A patent/CN102405048A/zh active Pending
- 2010-04-16 MX MX2011011119A patent/MX2011011119A/es active IP Right Grant
- 2010-04-16 SI SI201030759T patent/SI2421534T1/sl unknown
- 2010-04-16 MY MYPI2011004813A patent/MY155288A/en unknown
- 2010-04-16 PL PL10714164T patent/PL2421534T3/pl unknown
- 2010-04-16 CN CN201510093852.4A patent/CN104693145A/zh active Pending
- 2010-04-16 RS RSP20140505 patent/RS53539B1/en unknown
- 2010-04-16 UA UAA201113335A patent/UA106985C2/uk unknown
- 2010-04-16 JP JP2012506342A patent/JP5722879B2/ja active Active
- 2010-04-16 MA MA34385A patent/MA33298B1/fr unknown
- 2010-04-16 CA CA2759456A patent/CA2759456C/en active Active
- 2010-04-23 AR ARP100101364A patent/AR076400A1/es not_active Application Discontinuation
-
2011
- 2011-09-25 IL IL215362A patent/IL215362A0/en active IP Right Grant
- 2011-10-07 TN TNP2011000504A patent/TN2011000504A1/en unknown
- 2011-10-19 CR CR20110554A patent/CR20110554A/es unknown
- 2011-10-20 DO DO2011000319A patent/DOP2011000319A/es unknown
- 2011-10-21 ZA ZA2011/07731A patent/ZA201107731B/en unknown
- 2011-10-21 CL CL2011002631A patent/CL2011002631A1/es unknown
- 2011-10-24 CO CO11143307A patent/CO6450649A2/es active IP Right Grant
-
2012
- 2012-07-27 DO DO2012000211A patent/DOP2012000211A/es unknown
-
2014
- 2014-09-15 HR HRP20140880AT patent/HRP20140880T1/hr unknown
- 2014-10-29 SM SM201400159T patent/SMT201400159B/xx unknown
- 2014-12-11 US US14/567,003 patent/US9475748B2/en active Active
-
2015
- 2015-07-29 HK HK15107256.7A patent/HK1206732A1/xx unknown
-
2016
- 2016-09-21 US US15/271,543 patent/US10034876B2/en active Active
-
2018
- 2018-06-27 US US16/020,799 patent/US10857149B2/en active Active
-
2021
- 2021-05-10 AR ARP210101276A patent/AR122051A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201107731B (en) | Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine | |
| HK1165955A1 (en) | Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine 1-[2-(24-)] | |
| IL238068A0 (en) | New therapeutic uses of 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine | |
| HRP20170918T1 (hr) | Soli piperazina kao d3/d2 antagonista | |
| HRP20130819T1 (en) | New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine | |
| ME02307B (me) | Kristalni (r)-(e)-2-(4-(2-(5-(1-(3,5-diklorpiridin-4-il)etoksi)-1h-indazol- 3-il)vinil)-1h-pirazol-1-il)etanol i njegova upotreba kao inhibitora fgfr | |
| AP3583A (en) | Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine | |
| HK1140949A1 (en) | Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl) phenyl]piperidine 4-[2-(4-)-] | |
| CY1115793T1 (el) | Υγρα σκευασματα αλατων 1-[2-(2,4-διμεθυλοφαινυλοσουλφανυλο)φαινυλο]πιπεραζινης |